Gracell Biotechnologies Inc. (GRCL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.6600 |
| Open | 3.7100 |
| Bid | 3.5000 x 1400 |
| Ask | 3.6800 x 800 |
| Day's Range | 3.5100 - 3.8500 |
| 52 Week Range | 1.6800 - 18.4500 |
| Volume | |
| Avg. Volume | 214,804 |
| Market Cap | 243.783M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1320 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GRCL
Related Research
- Gracell Biotechnologies Inc.Daily – Vickers Top Buyers & Sellers for 05/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 days agoArgus Research
- PR Newswire
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:
- GlobeNewswire
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at AACR 2022; updated data to be presented at EHA 2022Oral presentation to highlight longer-term follow-up data from an IIT evaluating GC012F for relapsed/refractory multiple myeloma (RRMM) at ASCO 2022 and EHA 2022Plan to present initial data from an ongoing IIT evaluating GC012F for relapsed/
- PR Newswire
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress (EHA2022 Congress), being held from June 9 – June 12 in Vienna, Austria. The abstracts highlight the clinical data from ongoing investigator-initia
